HomePress-release

Redding, California - November 28, 2024

Minimal Residual Disease Testing Market to be Worth $4.45 Billion by 2031

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (PCR, Flow Cytometry, NGS), Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor), Sample (Blood, Bone Marrow) - Global Forecast to 2031

Meticulous Research^®—a leading global market research company, published a research report titled ‘Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (PCR, Flow Cytometry, NGS), Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor), Sample (Blood, Bone Marrow)—Global Forecast to 2031. According to this latest publication from Meticulous Research®, the minimal residual disease testing market is projected to reach $4.45 billion by 2031, at a CAGR of 14.6% during the forecast period 2024–2031.

The growth of the minimal residual disease testing market is driven by the growing burden of cancer, the extensive application of MRD in blood cancers, the high recurrence rates in some types of cancers, and growing investments and funding for MRD research and testing. Moreover, the rising adoption of personalized treatments & targeted therapies in the field of oncology and the growing use of MRD testing in cases of solid tumors are expected to generate market growth opportunities.

Key Players

The key players operating in the minimal residual disease testing market are Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Natera Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), Sysmex Corporation, (Japan), Integrated DNA Technologies, Inc. (U.S.), Twist Bioscience Corporation (U.S.), and Invivoscribe Inc. (U.S.).

Minimal Residual Disease Testing Market: Future Outlook

The minimal residual disease testing market is segmented based on offering, technology, application, sample type, and customer type. The report also evaluates industry competitors and analyzes the minimal residual disease testing market at the regional and country levels.

Among the offerings studied in this report, in 2024, the reagents & assays segment is anticipated to dominate the minimal residual disease testing market, with a share of 76.7%. The high burden of cancer, the repetitive use of assays & reagents, the intensive research and development activities by players in the market leading to the launch of new MRD testing products, and the significant use of MRD tests in cancer research and clinical trials are factors contributing to the segment’s dominant position in the minimal residual disease testing market.

Among the technologies studied in this report, in 2024, the flow cytometry segment is anticipated to dominate the minimal residual disease testing market, with a share of 42.7%. The cost-effectiveness of flow cytometry, the technology’s ability to simultaneously assess multiple parameters, such as cell size, granularity, and protein expression, and advancements in the technology are factors contributing to the segment’s dominant position in the minimal residual disease testing market.

Among the applications studied in this report, in 2024, the blood cancers segment is anticipated to dominate the minimal residual disease testing market. The high burden of blood cancers, the fast progression & high rates of recurrence of cancer, high investments in molecular residual disease testing for hematological malignancies, and the availability of a wide range of tests for blood cancers are factors contributing to the segment’s dominant position in the minimal residual disease testing market.

Among the sample types studied in this report, in 2024, the blood segment is anticipated to dominate the minimal residual disease testing market. The availability of a large number of blood-based MRD tests and more patient compliance with blood-based MRD tests compared to bone marrow-based MRD tests are major factors contributing to the segment’s dominant position in the minimal residual disease testing market.

Among the sample types studied in this report, in 2024, the pharmaceutical & biopharmaceutical companies segment is anticipated to dominate the minimal residual disease testing market. High investments by pharmaceutical & biopharmaceutical companies in oncology drug development, regulatory authorities’ encouragement to use MRD testing in clinical trials, and the high global cancer incidence are major factors contributing to the segment’s dominant position in the minimal residual disease testing market.

Geographic Review

This research report analyzes major geographies and provides a comprehensive analysis of the MRD testing market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa (UAE, South Africa, and Rest of Middle East & Africa).

Among the geographies studied in this report, in 2024, North America is anticipated to dominate the minimal residual disease testing market with a share of 38.8%. The high burden of cancer, extensive cancer-related R&D activities, and high awareness regarding MRD testing and its implementation in routine cancer treatments are major factors contributing to North America’s dominant position in the minimal residual disease testing market.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6068

Key Questions Answered in the Report:

What is the current revenue generated from the sale of minimal residual disease testing products across the globe?
At what rate is the demand for minimal residual disease testing products projected to grow for the next 5-7 years globally?
What is the historical market size and growth rate for minimal residual disease testing products across the globe?
What are the major factors impacting the growth of this market at the global and regional levels? What are the major opportunities for existing market players and new entrants in the market?
Which segments are creating major traction for the vendors in this market in terms of offering, technology, application, sample type, and customer type?
What are the key geographic trends in this market? Which regions/countries are expected to offer significant growth opportunities for the vendors operating in the minimal residual disease testing market?
Who are the major players in the minimal residual disease testing market? And what are their specific offerings in this market?
What are the recent key developments in the minimal residual disease testing market, and how are these strategic developments creating a global impact in this market?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - November 28, 2024

Minimal Residual Disease Testing Market to be Worth $4.45 Billion by 2031

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (PCR, Flow Cytometry, NGS), Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor), Sample (Blood, Bone Marrow) - Global Forecast to 2031

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies